How Automated Insulin Delivery Systems Work and What the Research Shows

Automated insulin delivery (AID), also called closed-loop insulin therapy, is a system with three essential components. The first is an insulin pump that delivers insulin. The second is a continuous glucose monitor (CGM) that tracks blood sugar levels. The third is an algorithm—essentially a set of instructions—that connects the pump and monitor so they can communicate.

Here's how it works in practice: the CGM measures your glucose levels and sends that information to the algorithm. The algorithm then tells the pump to increase, decrease, or pause insulin delivery to keep your blood sugar in a safe target range. This happens automatically and continuously, day and night, without you having to manually calculate and inject insulin doses.

Many endocrinologists now consider AID systems the standard of care for people with Type 1 diabetes because of their ability to reduce the burden of manual insulin management and improve glucose control.

Large studies comparing AID systems to traditional insulin therapy show consistent benefits. Across 65 clinical trials involving over 3,600 people with Type 1 diabetes, AID systems increased time in range (TIR)—the percentage of time blood sugar stays in target—by an average of 11.74 percentage points compared to standard insulin therapy.

Different AID systems show varying levels of performance. In a comprehensive analysis of seven different systems, the Minimed 780G achieved the highest time in range, followed by Control-IQ, Minimed 670G, and CamAPS Fx. However, all AID systems performed significantly better than insulin therapy without continuous glucose monitoring.

AID systems also reduced time below target range—the dangerous low blood sugar events—by between 2.79 and 3.69 percentage points, depending on the system. This is especially important because hypoglycemia (low blood sugar) poses real health risks and can be frightening, particularly for children and families.

The risk of severe hypoglycemia and diabetic ketoacidosis (DKA) with AID systems is similar to other types of insulin therapy, meaning these systems do not introduce new serious safety concerns. Research has not shown increased risk of these complications.

For pregnant women with Type 1 diabetes, AID systems offer particular promise. A controlled trial of 124 pregnant women found that those using hybrid closed-loop therapy spent 68.2% of the time in their pregnancy-specific target glucose range, compared to 55.6% in the standard insulin therapy group—a meaningful 10.5 percentage point difference. This matters because maintaining better glucose control during pregnancy benefits both mother and baby.

Some real-world studies have noted a modest increase in body weight in some long-term AID users, and researchers are continuing to study whether this represents a metabolic trade-off of improved glycemic control.

Research suggests certain groups may see larger improvements from AID systems. People who have had Type 1 diabetes for more than 20 years experienced more pronounced reductions in low blood sugar events. Similarly, people whose baseline glucose control was already relatively good (glycated hemoglobin below 7.5%) saw greater improvements in time below range.

AID systems have been studied in children, adolescents, and adults, making them relevant across the lifespan. However, the technology does require commitment to wearing both a pump and CGM and to engaging with the system regularly.

The rapid expansion of AID research—with half of all published studies appearing in just the last five years—reflects growing interest in these technologies. Ongoing studies are investigating long-term outcomes, including whether improvements in glucose control remain stable over years, and how these systems affect quality of life and treatment satisfaction.

If you're considering an AID system, these research findings can inform conversations with your diabetes care team. Different systems have different performance profiles, and what works best depends on your individual needs, lifestyle, and treatment goals.

Origin: YouTube / Omnipod Canada (Video report). Evidence: Video report, corroborated with 5 indexed studies. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.